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Background: In the present study we identified a novel gene, Homo Sapiens Chromosome 1 ORF109 (c1orf109,
GenBank ID: NM_017850.1), which encodes a substrate of CK2. We analyzed the regulation mode of the gene, the
expression pattern and subcellular localization of the predicted protein in the cell, and its role involving in cell
proliferation and cell cycle control.
Methods: Dual-luciferase reporter assay, chromatin immunoprecipitation and EMSA were used to analysis the basal
transcriptional requirements of the predicted promoter regions. C1ORF109 expression was assessed by western blot
analysis. The subcellular localization of C1ORF109 was detected by immunofluorescence and immune colloidal gold
technique. Cell proliferation was evaluated using MTT assay and colony-forming assay.
Results: We found that two cis-acting elements within the crucial region of the c1orf109 promoter, one TATA box
and one CAAT box, are required for maximal transcription of the c1orf109 gene. The 5′ flanking region of the
c1orf109 gene could bind specific transcription factors and Sp1 may be one of them. Employing western blot
analysis, we detected upregulated expression of c1orf109 in multiple cancer cell lines. The protein C1ORF109 was
mainly located in the nucleus and cytoplasm. Moreover, we also found that C1ORF109 was a phosphoprotein
in vivo and could be phosphorylated by the protein kinase CK2 in vitro. Exogenous expression of C1ORF109 in
breast cancer Hs578T cells induced an increase in colony number and cell proliferation. A concomitant rise in levels
of PCNA (proliferating cell nuclear antigen) and cyclinD1 expression was observed. Meanwhile, knockdown of
c1orf109 by siRNA in breast cancer MDA-MB-231 cells confirmed the role of c1orf109 in proliferation.
Conclusions: Taken together, our findings suggest that C1ORF109 may be the downstream target of protein kinase
CK2 and involved in the regulation of cancer cell proliferation.
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CK2 (formerly known as casein kinase II) is a ubiquitous,
highly conserved and messenger-independent protein
serine/threonine kinase composed of two catalytic α
subunits (αα, αα′, or α′α′) and two regulatory β subunits
in eukaryotic cells [1,2]. To date, more than 300 potential
substrates located in various compartments of the cell
have been identified [3]. A unique property of CK2 is that* Correspondence: liyugene@hit.edu.cn
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reproduction in any medium, provided the orit can use both ATP and GTP as the phosphate donor.
CK2 plays a global role in cell cycle progression, cell
growth and proliferation, cell survival and cell death [4-8].
Lack of any on/off regulatory mechanism, CK2 is constitu-
tively active in cells. It was postulated that the intracellular
dynamic shuttling of CK2 might represent a general
mechanism of its regulation [9]. Emerging evidence shows
that CK2 signaling is dysregulated in many human dis-
eases, including cancer. CK2 is upregulated in all cancers
that have been examined [10-12]. Although the kinase has
been studied for over 50 years, its physiological role andThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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elucidated.
The identification of cancer associated molecular altera-
tions has exploited many insights into the roles of onco-
genes or tumor suppressor genes in cancer progression.
Previously, we obtained an unknown cDNA fragment
named OPB7-1, which had different expression levels in
two human lung cancer cell lines with different metastasis
potentials [13]. Next, we mapped it to human chromosome
1p34 by radiation hybridization mapping [14]. Bioinfor-
matic methods, RACE (rapid amplification of cDNA ends)
and sequencing were performed to obtain the 3′ and 5′
ends of the gene from normal human lung tissue. BLASTN
results revealed that this cDNA sequence was homologous
with Homo Sapiens Chromosome 1 ORF109 (c1orf109, Gen-
Bank ID: NM_017850.1). The mRNA sequences of
c1orf109 are divided into five exons by four introns. The
hypothetical protein C1ORF109 consists of 203 amino
acids, and the predicted molecular weight and pI are
23.4kD and 5.47 respectively. However, no functional study
on c1orf109 has been reported.
In order to investigate the biological function of c1orf109
in the cell, we analyzed the putative promoter and the
biological features using bioinformatic tools. Meanwhile,
we identified the existence and subcellular location of en-
dogenous C1ORF109 protein. In addition, we also investi-
gated the role of c1orf109 gene involving in cancer cell
proliferation.Methods
Cell lines and reagents
HEK293, HeLa, MDA-MB-231 and Hs 578 T cells were
purchased from American Type Culture Collection
(ATCC). All cells were cultured in accordance with the
recommendations of ATCC. Oligonucleotides were synthe-
sized by Invitrogen. Anti-Flag M5 and anti-C1ORF109 anti-
bodies were from Sigma-Aldrich. Anti-phosphoserine
antibodies were from BD. Anti-PCNA and anti-cylcinD1
antibodies were from Abcam plc.Generation of c1orf109 promoter-luciferase constructs
PCR amplification was performed with c1orf109-specific
primers to clone the putative c1orf109 5′ proximal pro-
moter. An approximately 1.8 kb fragment that contained
the immediate 5′-flanking sequence of the putative
c1orf109 promoter (Genbank ID: AC104336) was amplified.
This 1.8 kb fragment was subcloned into the pGL3-basic
vector (Promega). The complete sequence was identified
with sequencing by the 3130 Genetic Analyzer (Applied
Biosystems). Progressive 5′ deletions and site-directed
mutations of putative cis-elements were achieved by PCR
with the primers listed in Table 1.Transient transfection and dual-luciferase assay
HEK293 cells were transiently transfected with various
c1orf109 promoter-luciferase constructs by Lipofectamine
2000 Reagent (Invitrogen). About 2×105 HEK293 cells in
each well of a 24-well plate were transfected with 1.0 μg of
each pGL3-c1orf109 promoter construct plus 50 ng of the
phRL-SV40 vector. The firefly luciferase activity was exam-
ined 24 hr after transfection using the Dual-Luciferase Re-
porter Assay System (Promega). Renilla luciferase activity
was used as an internal control. Each experiment was
repeated at least three times.
Electrophoretic mobility shift assay (EMSA)
EMSA was performed using Chemiluminescent EMSA
Kit (Beyotime). Briefly, 5 μg of nuclear extract was
incubated with 10 ng of each biotin-labeled probe in
binding buffer for 30 min at room temperature.
Meanwhile, reactions contained a 100-fold excess of
the same unlabeled probe, and other unrelated probes
were used to determine specific and nonspecific bind-
ing. Furthermore, specific antibodies against Sp1 for
supershift assay were performed in other reactions.
Then the reaction mixtures were separated in a 4 %
nondenaturing polyacrylamide gel in 0.5 ×TBE at
60 V for 2 hours. Then the DNA/protein complex
was transferred to nylon membrane, conjugated with
Streptavidin-HRP, visualized with ECL, and detected
by the Odyssey Fc Imaging System. The probes used
for EMSA are listed in Table I.
Chromatin immunoprecipitation (ChIP) assay
ChIP assays were performed as described previously [15]
with slight modification. About 1 × 107 cells were fixed
with 0.8 % formaldehyde for 10 min, lysed in 150 μl Buffer
A (10 mM Tris–HCl, pH 8.0, 10 mM NaCl, 0.2 % NP40)
for 10 min on ice. Spin down the precipitation and resus-
pend in 1 ml Buffer B (50 mM Tris–HCl, pH 8.0, 10 mM
EDTA, 1 % SDS). The lysate was fragmented by sonication
to yield fragments between 200 bp and 1000 bp, and then
centrifuged at 13,000 g for 15 min at 4°C. The supernatant
was whole cell extract (WCE). Three μg of anti-Sp1 anti-
body was added into tubes containing 200 μl WCE plus
300 μl Buffer C (16.7 mM Tris–HCl, pH 8.0, 167 mM
NaCl, 1.2 mM EDTA, 0.01 % SDS, 1.1 % Triton X-100).
After incubation, the antibody complexes were collected
with protein A agarose beads and subjected to serial
washes. Cross-linked chromatin was reversed at 65°C in
the presence of 200 mM NaCl for 5 hr. The DNA frag-
ments were then purified using chloroform-isoamyl alco-
hol. The PCR primers used to amplify the endogenous
c1orf109 promoter were listed in Table 1. PCR products
were then run on an agarose gel and photographed.
Meanwhile, DNA fragment extracted from 200 μl WCE
was saved as positive control. Another pair of primers
Table 1 Sequences of oligonucleotides used in promoter cloning and site-directed mutagenesis
Oligonucleotide Sequence (5′ to 3′) Purpose
PR CGAGATCTCGTGCCTGGCTACTGAGTCGC promoter cloning
PF-1795 CGACGCGTCGAGTTGTGGTCCAGGCTTGTTTCCC promoter cloning
PF-428 CGACGCGTCGTTCCAGCCTCTCGGTTTCAGGG promoter cloning
PF-216 CGACGCGTCGCTAACAGGACATGCCACCAC promoter cloning
PF-177 CGACGCGTCGCCGCAGGCTGACAAATGAGAAG promoter cloning
PF-93 CGACGCGTCGCCACATGTTGGACTACAGTAC promoter cloning
CAAT I mutR TGGGACTGGATGTTGGGACCG mutagenesis
CAAT II mutR TTAAACTGGGTGGCGGTGGTG mutagenesis
CAAT III mutR GACACTGTGTATCACAACCAACTGGC mutagenesis







ChIP InpF GGGTTCTCACGCTTTGGCTGTC ChIP
ChIP InpR CCGCTCTTTTAAATCTGGGA ChIP
GC box ACCCGGCTCCGCCCTGGCCGGCT EMSA
Note: The underlined letters indicate mutated nucleotides.
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~60 bp to ~900 bp downstream of the the transcriptional
start site (TSS) was used as negative control.
Phosphorylation by CK2 in vitro
The phosphorylation of the recombinant full-length
C1ORF109 protein by CK2 in vitro was detected using the
Casein Kinase 2 Assay Kit (Upstate). This assay is based
on phosphorylation of a CK2 substrate using the transfer
of the γ-phosphate of [γ-32P]-ATP by CK2 kinase. The
phosphorylated substrate was separated from the residual
[γ-32P]-ATP using P81 phosphocellulose paper, and [32P]
incorporation into the substrate was measured using a
scintillation counter and expressed as the calculated pmol
phosphate incorporated into CK2 substrate peptide/min/
ng of CK2.
To further verify C1ORF109 phosphorylation by CK2,
about 0.1 μg of recombinant full-length C1ORF109 protein
was incubated with human CK2 (Upstate) in Hybrid Buffer
(25 mM Tris–HCl, pH 7.5, 25 mM NaCl, 5 mM MgCl2,
1 mM DTT) and 0.1 mM ATP plus 4 μCi [γ-32P]-ATP
(3000 Ci/mM) for 30 min at 25°C [16], and fractionated by
SDS-PAGE. Dried Coomassie blue-stained gels were ana-
lyzed by the Storage Phosphor System (Cyclone).
siRNA and c1orf109 stably expressing cells
siRNA oligonucleotides were synthesized, and the
sequences of the siRNA for human c1orf109 was 5′-
UGGAAUGGUUGCAGGAUAUTT3′. A non-targetingsiRNA, 5′-UUCUCCGAACGUGUCACGUTT-3′, was
used as a negative control. MDA-MB-231 cells were trans-
fected with siRNA oligonucleotides using Lipofectamine
2000 Reagent (Invitrogen). Wild type c1orf109 was cloned
into the pcDNA3.1-Flag vector. Hs578T cells were stably
transfected with pcDNA3.1 or c1orf109 using Lipofecta-
mine 2000 Reagent followed by G418 (Merck) selection.
Cell proliferation assay
Proliferation was analyzed using MTT assay and colony-
forming assay. In the MTT assay, 3× 103 cells were plated
in 100 μl media per well in 96-well dishes, the medium was
removed and replaced with 100 μl fresh culture medium
containing 1.2 mM MTT at the indicated time points. The
reaction was incubated at 37°C for 4 hr. Next, 100 μl of
SDS-HCl solution (10 % SDS, 0.01 M HCl) was added to
each well. After incubation at 37°C for 4 hr, each sample
was mixed using a pipette, and absorbance was read at
570 nm. In the colony-forming assay, cells were plated in
6-well dishes at 500 cells/well. Every 4 days, the medium
was replaced with fresh medium. When the colonies were
clearly visible (after about two weeks), they were stained
with crystal violet and counted.
Immunoblotting
Cells were lysed in RIPA lysis buffer (50 mM Tris–HCl, pH
7.4, 150 mM NaCl, 1 % NP-40, 0.1 % SDS, and 0.5 %
sodium deoxycholate) containing 10 μg/ml aprotinin,
10 μg/ml leupeptin, and 1 mM PMSF. Equal amounts of
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amide gels, and proteins were transferred to a nitrocellulose
membrane. Membranes were blocked with 5 % defatted
milk and probed with the indicated primary antibodies, and
were incubated with secondary antibodies conjugated with
horseradish peroxidase. The ECL western blotting analysis
system was used to detect the substrates.Flow cytometric analysis
Cells were harvested and fixed in 70 % ice-cold ethanol
for 10 minutes and incubated with RNase A (100 μg/ml)
and propidium iodide (50 μg/ml) for 30 minutes, and
1× 104 cells from each sample were subjected to fluores-
cence-activated cell sorter scan (Becton Dickinson)
analysis.Statistical analysis
Statistical analysis was conducted using the two-tailed
Student’s t test and one-way ANOVA where appropriate.
The data were presented as means ± S.D. obtained from
three independent experiments. Results were considered
to be statistically significant at P< 0.05.Results and discussion
Identification of cis-acting elements in the c1orf109
promoter region
Because c1orf109 is a novel gene, its mechanism of regu-
lation is unclear. To analyze the putative promoter of
the human c1orf109 gene, an approximately 1.8 kb DNA
sequence located upstream of the TSS was cloned as
described in the Methods and Materials section. Nucleo-
tide sequence analysis of the 5′ flanking region of the
c1orf109 gene using MatInspector online software
revealed the presence of one TATA box (at −48 bp) and
three CAAT boxes (at −135 bp, -200 bp, -293 bp re-
spectively), as shown in Figure 1A. Progressive 5′ dele-
tions of the c1orf109 gene promoter constructs were
generated to identify transcriptional regulatory elements
(Figure 1B). All truncated constructs were transiently
transfected into HEK293 cells. Firefly luciferase activity
was normalized by co-transfection with a Renilla lucifer-
ase vector. Meanwhile, the promoter-less pGL3-basic
vector was used as a negative control. Significant lucifer-
ase activity was observed after transfection of the con-
struct containing the proximal 93 bp region upstream of
the TSS. Transfection of sequences further upstream,
from −177 to −428 bp, resulted in a significant increase
in promoter activity, whereas transfection of the prox-
imal 41 bp did not generate luciferase activity. The
results indicate that the region from −41 to −177 bp
contains positive regulatory elements essential for
achieving maximal c1orf109 promoter activity.To further identify the functional significance of the
potential transcription factor binding sites within the
region of −41 to −177 bp, including the putative CAAT
boxes and TATA box, serial site-directed mutation con-
structs were used to analyze their effects on luciferase ac-
tivity in HEK293 cells. Disruption of the CAAT I and
TATA box sites caused impaired promoter activity by ap-
proximately 44 to 47 percent. In contrast, mutations of
the CAAT box II or CAAT box III sites did not affect
c1orf109 promoter activity (Figure 2). Therefore, we con-
clude that CAAT box I and TATA box act as important
cis-acting elements within the c1orf109 promoter.Participation of Sp1 in c1orf109 transcription
Sp1 is a transcription factor that either enhances or
represses the activity of promoters of genes involved in
differentiation, cell cycle progression, and oncogenesis
[17]. The presence of several potential GC boxes sug-
gested that transcriptional factor Sp1 may be involved in
the transcriptional regulation of c1orf109 gene. To con-
firm whether Sp1 directly interact with c1orf109 promoter,
chromatin immunoprecipitation (ChIP) assay was per-
formed. HeLa cells were fixed, lysed and fragmented as
described in methods and materials. DNA was optimally
sheared with a distribution of fragments from 200 to1000
bp, as shown in Figure 3A. Immunoprecipitation of DNA/
protein complexes using antibodies against Sp1 was
followed by PCR amplification. As shown in Figure 3B,
anti-Sp1 antibody was capable of immunoprecipitating the
c1orf109 promoter fragment containing the GC box 4
(Figure 3B, lane 9); however, primers ChIP InpF/R failed
to produce a PCR product (Figure 3B, lanes 4, 8 and 12),
indicating that Sp1 directly interacted with c1orf109 pro-
moter region.
To detect whether Sp1 interacts directly with the po-
tential GC boxes, an electrophoretic mobility shift assay
(EMSA) was performed. Oligonucleotides corresponding
to the binding sites for Sp1 in the c1orf109 promoter
were designed (Table I). According to the results of
EMSA (Figure 3C), the mobility of labeled probes corre-
sponding to GC box 4 was shifted in the presence of nu-
clear protein prepared from HeLa cells. The binding
specificity of each probe was verified by supershift when
we added anti-Sp1 anitibody or excessive unlabeled
oligonucleotide competitors. These data suggest that the
CAAT box and TATA box are required for achieving the
basal transcription of the c1orf109 gene. The 5′ flanking
region of the c1orf109 gene could bind specific tran-
scription factors and Sp1 may participate in the regula-
tion of transcriptional expression of the gene. The
activation of transcription by CAAT box and TATA box
may be further modulated by GC box.
Figure 1 Identification of essential cis-acting elements within the c1orf109 promoter. (A) DNA sequence analysis of the 5′ flanking region of
human c1orf109 gene. The nucleotide sequence is numbered with the transcriptional start site (TSS) as +1 (dark arrow). MatInspector online software was
used to predict the putative transcription factor binding sites, which are underlined and indicated by name. (B) Deletion analysis of the c1orf109 promoter.
The truncated promoter fragments were inserted into the luciferase reporter vector pGL3-basic (Luc). Approximately 2×105 HEK293 in each well of 24-well
plate were transfected with 1.0 μg each of pGL3-c1orf109 promoter constructs plus 50 ng of phRL-SV40 vector. The firefly luciferase activity was assayed
24 hr after transfection and normalized to Renilla luciferase activity. Values are represented by means±S.D. obtained from three independent experiments.
Deletion from −177 to −101 bp and −101 to −41 bp led to extreme reduction of activity. The region within −177 bp of the c1orf109 promoter contains
multiple potentially important transcription factor binding sites including CAAT and TATA boxes.
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Previously, we have reported that c1orf109 exhibited an
increased expression in lung cancer tissues compared to
paired adjacent non-tumor tissues using in situ
hybridization with specific RNA probes [14]. To further
identify the existence and expression pattern of the puta-
tive protein C1ORF109 in the cell, the expression of
c1orf109 in 11 breast cancer cell lines and a melanomacell line were detected by immunoblotting. Meanwhile, a
non-tumorigenic epithelial cell line (MCF10A) [18] and
an immortalized human keratinocyte cell line (HaCaT)
[19] were used as control. As shown in Figure 4A,
C1ORF109 levels were upregulated in tumorigenic cell
lines compared to the control, especially in the cell lines
derived from metastatic sites, such as the cell lines
derived from pleural effusion (MDA-MB-436, MDA-
Figure 2 Effects of site-directed mutations on the c1orf109 promoter activity. HEK293 cells were transiently transfected with the −428 bp
region of c1orf109 promoter constructs with different mutations of CAAT or TATA box sites. The firefly luciferase activity was assayed 24 hr after
transfection and normalized to Renilla luciferase activity. Values represent the means ± S.D. of three independent experiments. * P< 0.05 versus
the wild type control.
Figure 3 Characterization of the transcription factors responsible for Sp1 binding sites in the c1orf109 gene promoter. (A) Distribution
of DNA fragments by sonication. DNA fragments were sheared with a distribution of fragments from 200 to1000 bp. (B) Chromatin
immunoprecipitation assay using HeLa cell lysates. Chromatin was immunoprecipitated using antibody against Sp1. Lanes 1, 5 and 9 were PCR
products from immunoprecipitation using primers ChIP 1 F/R, ChIP 2 F/R and ChIP 3 F/R respectively. Lanes 2, 6 and 10 were PCR products from
WCE using primers ChIP 1 F/R, ChIP 2 F/R and ChIP 3 F/R respectively. Lane 3, 7 and 11 were PCR products using ChIP InpF/R from WCE. Lanes 4,
8 and 12 were PCR products using ChIP InpF/R from immunoprecipitation. WCE, whole cell extract. (C) Biotin labeled oligonucleotides
corresponding to GC boxes were used in an EMSA with nuclear proteins from HeLa cells. Specific shift-bands are indicated with closed
arrowheads. NE, nuclear extract; SC, 100× specific competitors; NSC, 100× nonspecific competitors.
Liu et al. Journal of Biomedical Science 2012, 19:49 Page 6 of 11
http://www.jbiomedsci.com/content/19/1/49
Figure 4 (See legend on next page.)
Liu et al. Journal of Biomedical Science 2012, 19:49 Page 7 of 11
http://www.jbiomedsci.com/content/19/1/49
(See figure on previous page.)
Figure 4 C1ORF109 is upregulated in multiple cancer cells and located in both the nucleus and cytoplasm. (A) C1ORF109 expression in 11
human breast cancer cell lines and one melanoma cell lines were detected by western blot analysis. The non-tumorigenic epithelial cell line MCF 10A and
an immortalized human keratinocyte cell line HaCaT were used as control. (B) Immunofluorescence analysis showed the subcellular localization of
C1ORF109 using an anti-Flag tag antibody. (C) Immunoelectron microscope with colloidal gold showed the subcellular localization of C1ORF109 using an
anti-V5 epitope antibody. Arrows indicate the specific binding of gold particles. Nu, nucleus. C, cytoplasm. (D) The subcellular localization of endogenous
C1ORF109 was detected in HeLa cells using anti-C1ORF109 antibody.
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SK-BR-3), and ascites (ZR-75-30). Furthermore, we also
found that C1ORF109 was overexpressed in hepatocellu-
lar cancer tissues compared to paired adjacent non-tu-
morous tissues by quantitative real-time PCR (qRT-
PCR) (see Additional file 1). These findings indicate thatFigure 5 CK2 phosphorylates C1ORF109 in vitro. (A) C1ORF109-Flag wa
anti-phosphoserine. (B) C1ORF109-Flag purified from HEK293 cells was trea
immunoblotted for C1ORF109. (C) C1ORF109-Flag immunoprecipitated from
the CPM was read in a scintillation counter subsequently. (D) C1ORF109-Fla
and [γ-32P]-ATP, fractionated by SDS-PAGE, and dried Coomassie blue-stain
10 μg/ml. (E) Wild type C1ORF109 and C1ORF109Mut immunoprecipitated
respectively, and the CPM was read in a scintillation counter subsequently.increased expression of C1ORF109 may be involved in
cancer progression.
Subcellular localization of C1ORF109
The subcellular localization of the C1ORF109 protein
was also examined using immunofluorescence. cDNAs immunoprecipitated from HEK293 cells and was immunoblotted for
ted or mock treated with calf intestinal phosphatase (CIP) and
HEK293 cells was incubated with human CK2, and [γ-32P]-ATP, and
g purified from HEK293 cells was phosphorylated with human CK2
ed gels were examined by autoradiography. Heparin was used at
from HEK293 cells were incubated with human CK2, and [γ-32P]-ATP
Figure 6 c1orf109 is involved in the regulation of cancer cell proliferation. (A) MDA-MB-231 cells were transiently transfected with c1orf109-
siRNA and were subcultured for an additional 4 days. Cell proliferation was assessed by MTT assay. A non-targeting siRNA was used as a negative
control. (B) Hs578T cells were stably transfected with pcDNA3.1/c1orf109 construct. Cell proliferation was assessed by colony forming assay, as
described in the Methods section. A mock plasmid was used as a control. (C) The expression levels of PCNA and cyclinD1 were detected by
western blotting. (D) Cell cycle was assessed by PI staining.
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were cultured on a round coverslip and transiently
transfected with pCMV-Flag-c1orf109. A mock vector
was used as negative control. The cells were subse-
quently fixed, incubated with TRITC-labeled antibodies,
and analyzed by confocal microscopy. Positive signals
were found mainly in the nucleus and cytoplasm. No
signal was detected in the control cells (Figure 4B). To
confirm further the subcellular localization of
C1ORF109, an immune colloidal gold assay was per-
formed in NIH3T3 cells that stably expressed V5 tagged
C1ORF109. The samples were analyzed by transmission
electron microscope, and the results showed that thecolloidal gold particles (diameter, ~15 nm) mainly loca-
lized to the nucleus and cytoplasm (Figure 2C). In
addition, the subcellular localization of endogenous
C1ORF109 was detected in HeLa cells using anti-
C1ORF109 antibodies (Figure 2D). These data indicate
that C1ORF109 protein is mainly located in the nucleus
and cytoplasm.
Phosphorylation of C1ORF109 by CK2 in vitro
Since c1orf109 has been shown to be involved in cancer
progression, we focused on the biological functions of
c1orf109 in the cell. To determine the functional domain of
C1ORF109 at the molecular level, the PROSITE method
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tential CK2 phosphorylation sites at serines 104, 134 and
182 were found. Therefore, C1ORF109 is predicted to be a
phosphoprotein. The full-length C1ORF109 purified from
HEK293 cells was recognized by anti-phosphoserine anti-
bodies (Figure 5A). Moreover, treatment of C1ORF109
immunoprecipitated from HEK293 cells with calf intestinal
phosphatase (CIP) resulted in different electrophoretic
mobility compared with untreated C1ORF109 (Figure 5B).
Together, these data imply that C1ORF109 is a phospho-
protein in eukaryotic cells.
To test whether C1ORF109 is a substrate of protein
kinase CK2, the full-length C1ORF109 purified from
HEK293 cells was incubated with human CK2, [γ-32P]-
ATP in vitro, and the CPM was subsequently read in a
scintillation counter. To exclude the influence of PKA, a
PKA inhibitor cocktail was added to the reaction system.
The results indicate that C1ORF109 is efficiently phos-
phorylated by CK2 in vitro (Figure 5C). Meanwhile,
C1ORF109 phosphorylation was abolished by heparin,
which is a specific inhibitor of protein kinase CK2 (Fig-
ure 5D). Next, serines 104, 134 and 182 were converted
into nonphosphorylatable alanine residues yielding a
mutant C1ORF109. C1ORF109Mut cannot be phos-
phorylated by CK2 in vitro (Figure 5E). These findings
suggest that C1ORF109 is specifically phosphorylated by
CK2 in vitro, and that it is a substrate of the protein kin-
ase CK2.
Involvement of C1ORF109 in cancer cell proliferation
CK2, a ubiquitous protein serine/threonine kinase with
hundreds of substrates, is essential for the modulation of
cell growth and proliferation. Since C1ORF109 has been
identified to be a substrate of CK2, it might play a role in
the modulation of cell proliferation. To verify this postula-
tion, MDA-MB-231 cells, which express endogenous
C1ORF109 at high levels, were transiently transfected with
c1orf109-siRNA to knock down endogenous C1ORF109
and showed a reduction in cell viability (P< 0.05,
Figure 6A). However, Hs578T cells, which express low
levels of endogenous C1ORF109, were stably transfected
to overexpress exogenous C1ORF109 and showed a 5-fold
increase in colony number in colony-forming assays
(P< 0.05, Figure 6B).
The D-type cyclins (Dl, D2 and D3) are key governors of
the progression from G1 to S phase of the mammalian cell
cycle. These three D-type cyclins are expressed in overlap-
ping and apparently redundant fashion in proliferating
tissues [20,21]. PCNA, a regulator of DNA replication and
cell cycle control, is a well-defined cell proliferation par-
ameter [22,23]. We tested the effect of C1ORF109 overex-
pression or depletion on the expression levels of PCNA
and cyclinD1. Downregulation of PCNA and cyclinD1
were detected in C1ORF109-depleted cells. Meanwhile,Hs578T cells stably expressing exogenous C1ORF109
showed increased expression of PCNA and cyclinD1
(Figure 6C). In addition, the effect of c1orf109 on cell
cycle distribution was examined by flow cytometry.
Cell cycle analysis of MDA-MB-231 cells transfected
with c1orf109-siRNA showed an increase in G1 phase
and a reduction in DNA synthetic activity (S phase),
whereas stably expressing exogenous C1ORF109 in
Hs578T cells resulted in fewer cells accumulating in
G1 phase compared to the control (Figure 6D). These
results indicate that upregulation of c1orf109 in breast
cancer cells could promote cancer cell proliferation
in vitro, which is mainly due to the acceleration of
G1 to S phase transition.
Conclusions
In conclusion, our experiments show that the unknown
gene c1orf109 encodes a CK2 substrate and is involved in
the modulation of cell proliferation. More work will be
required to identify the molecular mechanisms by which
CK2 regulates the expression of C1ORF109 and then
affects cell proliferation.
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